acimmune.com - מכפיל EV/Sales ACIU

AC Immune is scaling its precision neurodegeneration therapy portfolio through global R&D partnerships. Long-term patents and upfront payments from pharma behemoths provide stable funding, while manufacturing outsourcing allows the company to focus on development. The enterprise value-to-revenue ratio illustrates the search for market equilibrium, while 5323.19 shows the current volume of the total valuation metric.
ACIU (AC Immune): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This ratio compares the enterprise value, including net debt, to the company's sales volume. By analyzing the EV/Revenue value on the GURU.Markets platform, an investor assesses the capitalization efficiency of operating income. The current level of 5323.19 reflects market expectations regarding the company's resilience to external shocks. This metric confirms the fundamental reliability of the business. The high authority of AC Immune (ACIU) in Alzheimer's therapy and its partnerships with pharma behemoths justify the current valuation.